Abstract CT169: Phase Ib/II open-label, randomized study of atezolizumab + regorafenib + AB928 or atezolizumab + regorafenib vs regorafenib for patients with microsatellite-stable, refractory metastatic colorectal cancer in MORPHEUS-CRC

Authors: James M. Cleary, Carlos Gomez-Roca, Francois Ghiringhelli, Joon Oh Park, Tae-You Kim, Brandon Beagle, Janelle Soong, Yibing Yan, Hans-Joachim Helms, Janet Lau, Edward Cha, Michel Ducreux

Published: 2025-04-25

DOI: 10.1158/1538-7445.am2025-ct169

Source: Full article